Matching articles for "COVID-19"
Issue 1759 · July 20, 2026 Free
Ensitrelvir (Xocova) for Post-Exposure Prophylaxis of COVID-19

The FDA has approved ensitrelvir ( Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis of COVID-19 in patients ≥12 years old who had contact with an infected individual.…

Med Lett Drugs Ther. 2026 Jul 20; 68(1759):113-4 doi:10.58347/tml.2026.1759a
The FDA has approved ensitrelvir ( Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis of COVID-19 in patients ≥12 years old who had contact with an infected individual. Ensitrelvir is the first oral antiviral drug to be approved in the US for this indication. The parenteral monoclonal antibody combinations bamlanivimab and etesevimab and casirivimab and imdevimab (REGEN-COV) are no longer authorized for postexposure prophylaxis of COVID-19 in the US.
Issue 1739 · October 13, 2025 Free
COVID-19 Update: 2025-2026 Vaccine Formulations and Recommendations

The FDA has licensed new 2025-2026 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax, mNEXSPIKE) and the adjuvanted protein subunit COVID-19 vaccine…

Med Lett Drugs Ther. 2025 Oct 13; 67(1739):166-8 doi:10.58347/tml.2025.1739d
The FDA has licensed new 2025-2026 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax, mNEXSPIKE) and the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax (Nuvaxovid) . The new formulations are indicated for use in all adults ≥65 years old and in persons 6 months (Spikevax) , 5 years (Comirnaty) , or 12 years (mNEXSPIKE, Nuvaxovid) through 64 years old who are at high risk for severe COVID-19 because of an underlying condition. An Emergency Use Authorization allowing administration of the Pfizer vaccine to children 6 months through 4 years old has been withdrawn.
Issue 1738 · September 29, 2025 Free
Influenza Vaccines for 2025-2026

Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed…

Med Lett Drugs Ther. 2025 Sep 29; 67(1738):153-8 doi:10.58347/tml.2025.1738a
Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
Issue 1733 · July 21, 2025 Free
COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19

The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe…

Med Lett Drugs Ther. 2025 Jul 21; 67(1733):119-20 doi:10.58347/tml.2025.1733h
The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe outcomes from COVID-19. Spikevax , the original Moderna mRNA COVID-19 vaccine, remains in production2; it is licensed for use in persons ≥12 years old and is available under an Emergency Use Authorization (EUA) for children 6 months to 11 years old.
Issue 1733 · July 21, 2025 Free
COVID-19 Update: mRNA COVID-19 Vaccines and Myocarditis

The FDA has required the manufacturers of the mRNA COVID-19 vaccines Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) to revise their labels to include updated information about the risks of…

Med Lett Drugs Ther. 2025 Jul 21; 67(1733):119 doi:10.58347/tml.2025.1733g
The FDA has required the manufacturers of the mRNA COVID-19 vaccines Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) to revise their labels to include updated information about the risks of myocarditis/pericarditis. The FDA requested that the manufacturers submit the proposed labeling changes or contest the agency's requirement for the safety update by May 17, 2025. As of June 4th, to our knowledge, the labels of Comirnaty and Spikevax have not been updated and neither manufacturer has submitted a rebuttal.
Issue 1714 · October 28, 2024 Free
COVID-19 Update: Novavax Vaccine for 2024-2025

A 2024-2025 formulation of the Novavax adjuvanted protein subunit COVID-19 vaccine that more closely targets currently circulating SARS-CoV-2 variants is available now under an FDA Emergency Use Authorization…

Med Lett Drugs Ther. 2024 Oct 28; 66(1714):175-6 doi:10.58347/tml.2024.1714d
A 2024-2025 formulation of the Novavax adjuvanted protein subunit COVID-19 vaccine that more closely targets currently circulating SARS-CoV-2 variants is available now under an FDA Emergency Use Authorization (EUA) for use in persons ≥12 years old. The 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were licensed by the FDA last month for use in persons ≥12 years old and made available under EUAs for use in persons 6 months to 11 years old.
Issue 1713 · October 14, 2024 Free
Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only)

A reader of our article on the 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) asked us to provide more information on the data that…

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):e168 doi:10.58347/tml.2024.1713h
A reader of our article on the 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) asked us to provide more information on the data that supported their licensure.
Issue 1711 · September 16, 2024 Free
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2024-2025

New 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) that more closely target currently circulating variants have been licensed by the FDA…

Med Lett Drugs Ther. 2024 Sep 16; 66(1711):151-2 doi:10.58347/tml.2024.1711c
New 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) that more closely target currently circulating variants have been licensed by the FDA for persons ≥12 years old and made available under FDA Emergency Use Authorizations (EUAs) for use in persons 6 months to 11 years old.1-3 A 2024-2025 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax is expected to become available soon for persons ≥12 years old.
Issue 1702 · May 13, 2024 Free
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis

The FDA has issued an Emergency Use Authorization (EUA) for the long-acting investigational IV monoclonal antibody pemivibart ( Pemgarda – Invivyd) for pre-exposure prophylaxis of COVID-19 in persons ≥12…

Med Lett Drugs Ther. 2024 May 13; 66(1702):79-80 doi:10.58347/tml.2024.1702e
The FDA has issued an Emergency Use Authorization (EUA) for the long-acting investigational IV monoclonal antibody pemivibart ( Pemgarda – Invivyd) for pre-exposure prophylaxis of COVID-19 in persons ≥12 years old (weight ≥40 kg) who have moderate to severe immune compromise and are unlikely to respond adequately to COVID-19 vaccination (see Table 1). Pemgarda is the only drug that is currently authorized in the US for pre-exposure prophylaxis of COVID-19. Tixagevimab/cilgavimab (Evusheld) was previously available under an EUA for this indication, but it lacks activity against currently circulating SARS-CoV-2 variants.
Issue 1689 · November 13, 2023 Free
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024

A new 2023-2024 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax that was developed to more closely target currently circulating SARS-CoV-2 variants has been made…

Med Lett Drugs Ther. 2023 Nov 13; 65(1689):182-3 doi:10.58347/tml.2023.1689b
A new 2023-2024 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax that was developed to more closely target currently circulating SARS-CoV-2 variants has been made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12 years old. The original formulation of the Novavax vaccine is no longer authorized for use in the US. In September, updated formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were licensed by the FDA for use in persons ≥12 years old and made available under EUAs for use in persons 6 months to 11 years old.
Issue 1689 · November 13, 2023 Free
Correction

In our article in issue 1687 on the updated 2023-2024 COVID-19 vaccines from Pfizer and Moderna (Med Lett Drugs Ther 2023; 65:161), the doses and formulations of the Pfizer vaccine were incorrect. A revised…

Med Lett Drugs Ther. 2023 Nov 13; 65(1689):184 doi:10.58347/tml.2023.1689d
In our article in issue 1687 on the updated 2023-2024 COVID-19 vaccines from Pfizer and Moderna (Med Lett Drugs Ther 2023; 65:161), the doses and formulations of the Pfizer vaccine were incorrect. A revised table has been posted in the online version of the article.
Issue 1687 · October 16, 2023 Free
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024

New 2023-2024 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and that more closely target currently circulating variants have been licensed by the FDA for use in persons…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):167-8 doi:10.58347/tml.2023.1687c
New 2023-2024 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and that more closely target currently circulating variants have been licensed by the FDA for use in persons ≥12 years old and made available under FDA Emergency Use Authorizations (EUAs) for use in persons 6 months to 11 years old. The bivalent (original and Omicron BA.4/5) formulations of the Pfizer and Moderna vaccines are no longer authorized for use in the US.
Issue 1687 · October 16, 2023 Free
Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines (online only)

View the Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):e1 doi:10.58347/tml.2023.1687e
View the Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines
Issue 1677 · May 29, 2023 Free
COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19

The investigational anti-complement component 5a (C5a) antibody vilobelimab ( Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with…

Med Lett Drugs Ther. 2023 May 29; 65(1677):86-7 doi:10.58347/tml.2023.1677d
The investigational anti-complement component 5a (C5a) antibody vilobelimab ( Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with COVID-19 beginning within 48 hours after invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) is started. Vilobelimab is the first anti-C5a antibody to become available in the US.
Issue 1677 · May 29, 2023 Free
COVID-19 Update: Metformin to Prevent Long Covid?

Results from a double-blind trial suggest that off-label use of the oral antihyperglycemic drug metformin in patients with COVID-19 may decrease the risk of post-acute sequelae of SARS-CoV-2 infection ("long…

Med Lett Drugs Ther. 2023 May 29; 65(1677):87-8 doi:10.58347/tml.2023.1677e
Results from a double-blind trial suggest that off-label use of the oral antihyperglycemic drug metformin in patients with COVID-19 may decrease the risk of post-acute sequelae of SARS-CoV-2 infection ("long COVID").
Issue 1675 · May 1, 2023 Free
Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines (online only)

View the Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines

Med Lett Drugs Ther. 2023 May 1; 65(1675):e1 doi:10.58347/tml.2023.1675f
View the Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines
Issue 1675 · May 1, 2023 Free
Dosing Recommendations for Novavax and Johnson & Johnson COVID-19 Vaccines (online only)

View the Dosing Recommendations for Novavax and Johnson & Johnson COVID-19 Vaccines

Med Lett Drugs Ther. 2023 May 1; 65(1675):e1 doi:10.58347/tml.2023.1675g
View the Dosing Recommendations for Novavax and Johnson & Johnson COVID-19 Vaccines
Issue 1674 · April 17, 2023 Free
COVID-19 Update: Pfizer Bivalent Vaccine Booster Dose for Children 6 Months to 4 Years Old

The FDA has expanded its Emergency Use Authorization (EUA) for the COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to permit use of the bivalent formulation (containing mRNA from the original and…

Med Lett Drugs Ther. 2023 Apr 17; 65(1674):63-4 doi:10.58347/tml.2023.1674c
The FDA has expanded its Emergency Use Authorization (EUA) for the COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to permit use of the bivalent formulation (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children 6 months to 4 years old who completed the primary series with 3 doses of the monovalent formulation ≥2 months previously. The Pfizer bivalent vaccine had previously been authorized for use as a booster dose in persons ≥5 years old and as a third primary dose in children 6 months to 4 years old. Booster doses of the Moderna bivalent COVID-19 vaccine (Spikevax) for children 6 months to 5 years old were authorized earlier.
Issue 1671 · March 6, 2023 Free
Antiviral Drugs for COVID-19 in Vaccinated Outpatients

Three products are currently available in the US for treatment of high-risk,1 nonhospitalized adults with mild to moderate COVID-19: oral ritonavir-boosted nirmatrelvir (Paxlovid) , IV remdesivir (Veklury) ,…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):33-4 doi:10.58347/tml.2023.1671a
Three products are currently available in the US for treatment of high-risk,1 nonhospitalized adults with mild to moderate COVID-19: oral ritonavir-boosted nirmatrelvir (Paxlovid) , IV remdesivir (Veklury) , and oral molnupiravir (Lagevrio) . Remdesivir is FDA-approved for such use; nirmatrelvir/ritonavir and molnupiravir are available under an FDA Emergency Use Authorization. Because the pivotal clinical trials of these products for outpatient use were conducted in patients who were not vaccinated against COVID-19, some clinicians have questioned whether they can benefit vaccinated outpatients.
Issue 1669 · February 6, 2023 Free
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (online only)

The FDA has warned that the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) are unlikely to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2.…

Med Lett Drugs Ther. 2023 Feb 6; 65(1669):e25 doi:10.58347/tml.2023.1669e
The FDA has warned that the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) are unlikely to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2. Evusheld is available under an Emergency Use Authorization (EUA) for IM pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of a severe adverse reaction that prevents their vaccination against COVID-19 or moderate or severe immune compromise.
Issue 1667 · January 9, 2023 Free
COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):e9 doi:10.58347/tml.2023.1667d
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for treatment of children 2-17 years old who are hospitalized with COVID-19 and require oxygen support.
Issue 1666 · December 26, 2022 Free
COVID-19 Update: Bebtelovimab EUA Withdrawn (online only)

The FDA has withdrawn its Emergency Use Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) for treatment of COVID-19. Bebtelovimab is not…

Med Lett Drugs Ther. 2022 Dec 26; 64(1666):e209
The FDA has withdrawn its Emergency Use Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) for treatment of COVID-19. Bebtelovimab is not expected to retain activity against the Omicron variants BQ.1 and BQ.1.1, which currently cause the majority of COVID-19 cases in all regions of the US.
Issue 1665 · December 12, 2022 Free
An EUA for Anakinra (Kineret) for COVID-19 (online only)

The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19…

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e203-4
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are not commercially available in the US.
Issue 1665 · December 12, 2022 Free
COVID-19 Update: Bivalent Pfizer and Moderna Vaccines Authorized for Children ≥6 Months Old (Online Only)

The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these…

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e209-10
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) in children as young as 6 months. The bivalent Pfizer vaccine is authorized for use as the final dose of a 3-dose primary series in children 6 months to 4 years old. The bivalent Moderna vaccine is authorized for use as a booster dose in children 6 months to 5 years old who completed a primary series with the monovalent Moderna vaccine.1 Bivalent vaccines had previously been authorized for use as a booster dose in persons ≥5 years old (Pfizer) or ≥6 years old (Moderna).
Issue 1664 · November 28, 2022 Free
COVID-19 Update: Resistance to Bebtelovimab (online only)

The FDA has warned that the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab is not expected to retain activity against the Omicron variants BQ. and BQ.1.1.1 Bebtelovimab (LY-CoV1404 – Lilly)…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):e192
The FDA has warned that the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab is not expected to retain activity against the Omicron variants BQ. and BQ.1.1.1 Bebtelovimab (LY-CoV1404 – Lilly) is available under an FDA Emergency Use Authorization (EUA) for IV treatment of mild to moderate COVID-19 in high-risk patients ≥12 years old who weigh ≥40 kg for whom alternative treatment options are unavailable or inappropriate. The drug remains authorized for use in all regions of the US.
Issue 1662 · October 31, 2022 Free
COVID-19 Update: Novavax Vaccine Authorized for Booster Immunization (online only)

The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include its use as a first booster dose in adults who completed a primary…

Med Lett Drugs Ther. 2022 Oct 31; 64(1662):e1-2
The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include its use as a first booster dose in adults who completed a primary series with any COVID-19 vaccine ≥6 months previously and are unable or unwilling to receive a booster dose of a bivalent mRNA vaccine. The Novavax vaccine is not authorized for use in persons who have received a booster dose of any other COVID-19 vaccine.
Issue 1661 · October 17, 2022 Free
COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)

The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these…

Med Lett Drugs Ther. 2022 Oct 17; 64(1661):e1
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children as young as 5 years old (Pfizer) or 6 years old (Moderna). The bivalent Pfizer vaccine had previously been authorized for use in persons ≥12 years old and the bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for primary immunization against COVID-19. The monovalent Pfizer and Moderna COVID-19 vaccines are no longer authorized for use as booster doses in any age group.
Issue 1660 · October 3, 2022 Free
COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization

The FDA has amended its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of bivalent formulations of the…

Med Lett Drugs Ther. 2022 Oct 3; 64(1660):159-60
The FDA has amended its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of bivalent formulations of the products as a single booster dose in persons ≥12 years old (Pfizer) or ≥18 years old (Moderna) whose most recent COVID-19 vaccine dose was a monovalent product given ≥2 months previously as a booster or for completion of a primary series. The bivalent formulations are not authorized for primary immunization. Monovalent Pfizer and Moderna COVID-19 vaccines are no longer authorized for use as booster doses in persons ≥12 years old.
Issue 1660 · October 3, 2022 Free
COVID-19 Update: Novavax Vaccine Authorized for Adolescents 12-17 Years Old (online only)

The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include use of the vaccine as a two-dose primary series in adolescents 12-17…

Med Lett Drugs Ther. 2022 Oct 3; 64(1660):e160
The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include use of the vaccine as a two-dose primary series in adolescents 12-17 years old. The vaccine was authorized for primary immunization of adults in July 2022.
Issue 1656 · August 8, 2022 Free
COVID-19 Update: FDA Authorizes Novavax COVID-19 Vaccine

The FDA has issued an Emergency Use Authorization (EUA) for an adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax. The vaccine is indicated for use as a two-dose primary series to prevent…

Med Lett Drugs Ther. 2022 Aug 8; 64(1656):121-2
The FDA has issued an Emergency Use Authorization (EUA) for an adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax. The vaccine is indicated for use as a two-dose primary series to prevent COVID-19 in adults; it is not authorized for use in children or as a booster dose. Three other COVID-19 vaccines are available in the US for primary immunization of adults; the mRNA vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are FDA-licensed for this indication, and the adenovirus-based vaccine manufactured by Johnson & Johnson (Janssen) is available under an EUA for use in adults who are unable or unwilling to receive another COVID-19 vaccine.
Issue 1656 · August 8, 2022 Free
COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld) (online only)

The FDA has amended its Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab ( Evusheld – AstraZeneca) to recommend repeat dosing every 6…

Med Lett Drugs Ther. 2022 Aug 8; 64(1656):e122-3
The FDA has amended its Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab ( Evusheld – AstraZeneca) to recommend repeat dosing every 6 months in patients who require ongoing protection against COVID-19. Evusheld is authorized for IM pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of a severe adverse reaction that prevents their vaccination against COVID-19 or moderate or severe immune compromise
Issue 1656 · August 8, 2022 Free
COVID-19 Update: Prescription of Paxlovid by Pharmacists (online only)

The FDA has amended its Emergency Use Authorization (EUA) for Paxlovid (Pfizer), the investigational oral antiviral drug nirmatrelvir copackaged with oral ritonavir, to allow for it to be prescribed by…

Med Lett Drugs Ther. 2022 Aug 8; 64(1656):e124
The FDA has amended its Emergency Use Authorization (EUA) for Paxlovid (Pfizer), the investigational oral antiviral drug nirmatrelvir copackaged with oral ritonavir, to allow for it to be prescribed by licensed pharmacists in certain situations. Paxlovid is authorized for oral treatment of mild to moderate COVID-19 in high-risk outpatients ≥12 years old who weigh at least 40 kg. NIH guidelines list it as the treatment of choice for COVID-19 in high-risk adult outpatients.
Issue 1655 · July 25, 2022
Drugs for Treatment and Prevention of Venous Thromboembolism

Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for…

Med Lett Drugs Ther. 2022 Jul 25; 64(1655):113-20
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Issue 1654 · July 11, 2022 Free
COVID-19 Update: Pfizer/BioNTech and Moderna Vaccines Authorized for Children ≥6 Months Old

The FDA has expanded its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use in children as young as 6…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):110-2
The FDA has expanded its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use in children as young as 6 months old. The Pfizer vaccine was previously authorized for use in persons ≥5 years old, and the Moderna vaccine was authorized for use in adults ≥18 years old.
Issue 1654 · July 11, 2022 Free
COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld)

The labeling for the investigational, long-acting, prophylactic anti-SARS-CoV-2 monoclonal antibodies tixagevimab and cilgavimab ( Evusheld ; available under an FDA Emergency Use Authorization) now includes…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):112
The labeling for the investigational, long-acting, prophylactic anti-SARS-CoV-2 monoclonal antibodies tixagevimab and cilgavimab ( Evusheld ; available under an FDA Emergency Use Authorization) now includes warnings about a risk of serious hypersensitivity reactions, including anaphylaxis, with use of the drugs, particularly in patients who have experienced a hypersensitivity reaction to a COVID-19 vaccine.
Issue 1652 · June 13, 2022 Free
COVID-19 Update: NIH Recommends Against Ivermectin

On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized,…

Med Lett Drugs Ther. 2022 Jun 13; 64(1652):95-6
On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized, placebo-controlled trials of ivermectin have produced negative results and because alternative drugs that have been shown to be effective for treatment of COVID-19 are available.
Issue 1652 · June 13, 2022 Free
COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (online only)

The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal…

Med Lett Drugs Ther. 2022 Jun 13; 64(1652):e2-3
The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Baricitinib was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for use in children 2-17 years old hospitalized with COVID-19 who require oxygen support.
Issue 1652 · June 13, 2022 Free
COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old

The FDA has expanded its Emergency Use Authorization for the mRNA COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to include administration of a booster dose in children 5-11 years old who…

Med Lett Drugs Ther. 2022 Jun 13; 64(1652):94
The FDA has expanded its Emergency Use Authorization for the mRNA COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to include administration of a booster dose in children 5-11 years old who completed a primary series of the Pfizer vaccine ≥5 months previously.
Issue 1652 · June 13, 2022 Free
COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine

The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19…

Med Lett Drugs Ther. 2022 Jun 13; 64(1652):94-5
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.
Issue 1652 · June 13, 2022 Free
COVID-19 Update: Remdesivir (Veklury) FDA-Approved for Children <12 Years Old (online only)

IV antiviral drug remdesivir (Veklury) has now been FDA-approved for treatment of COVID-19 in patients ≥28 days old who weigh ≥3 kg and are either hospitalized or at high risk for progression to severe…

Med Lett Drugs Ther. 2022 Jun 13; 64(1652):e1
IV antiviral drug remdesivir (Veklury) has now been FDA-approved for treatment of COVID-19 in patients ≥28 days old who weigh ≥3 kg and are either hospitalized or at high risk for progression to severe disease. Remdesivir was already FDA-approved for these indications in patients ≥12 years old who weigh ≥40 kg; it was available under an Emergency Use Authorization (EUA) for younger or lighter patients. Remdesivir is the first drug to be FDA-approved for treatment of COVID-19 in children <12 years old.
Issue 1648 · April 18, 2022 Free
COVID-19 Updates

The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use as a second booster dose…

Med Lett Drugs Ther. 2022 Apr 18; 64(1648):63-4
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use as a second booster dose ≥4 months after a first booster dose in adults ≥50 years old and in persons aged ≥12 years (Pfizer) or ≥18 years (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent.
Issue 1646 · March 21, 2022 Free
An EUA for Bebtelovimab for Treatment of COVID-19

The investigational monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of mild to moderate COVID-19 in patients ≥12 years old…

Med Lett Drugs Ther. 2022 Mar 21; 64(1646):41-2
The investigational monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease, including hospitalization and death, and for whom alternative treatment options are unavailable or inappropriate. Bebtelovimab is active against the Omicron variant of SARS-CoV-2; sotrovimab (VIR-7831) is the only other monoclonal antibody currently available for treatment of COVID-19 that is active against Omicron.
Issue 1646 · March 21, 2022 Free
COVID-19 Updates

The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently…

Med Lett Drugs Ther. 2022 Mar 21; 64(1646):47-8
The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently recommends a 3-week interval between the first two doses of the Pfizer/BioNTech mRNA vaccine (Comirnaty) and a 4-week interval between the first two doses of the Moderna mRNA vaccine (Spikevax) . The new guidance is based on data suggesting that a longer interval can decrease the risk of myocarditis and may improve vaccine efficacy.
Issue 1644 · February 21, 2022 Free
COVID-19 Updates

The IV antiviral drug remdesivir (Veklury – Gilead) has been available for treatment of COVID-19 in hospitalized patients since 2020. Now, the FDA has approved remdesivir for treatment of mild to moderate…

Med Lett Drugs Ther. 2022 Feb 21; 64(1644):31-2
The IV antiviral drug remdesivir (Veklury – Gilead) has been available for treatment of COVID-19 in hospitalized patients since 2020. Now, the FDA has approved remdesivir for treatment of mild to moderate COVID-19 in outpatients ≥12 years old who weigh ≥40 kg and are at high risk for progression to severe disease, including hospitalization or death; they also issued an Emergency Use Authorization (EUA) allowing its use in any other high-risk outpatient who weighs ≥3.5 kg.
Issue 1643 · January 28, 2022 Free
Treatment of COVID-19 in High-Risk Outpatients (online only)

View the Treatment of COVID-19 in High-Risk Outpatients Chart

Med Lett Drugs Ther. 2022 Jan 28; 64(1643):e1
View the Treatment of COVID-19 in High-Risk Outpatients Chart
Issue 1642 · January 24, 2022 Free
Paxlovid for Treatment of COVID-19

On December 22, 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir ( Paxlovid – Pfizer) for…

Med Lett Drugs Ther. 2022 Jan 24; 64(1642):9-10
On December 22, 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir ( Paxlovid – Pfizer) for oral treatment of mild to moderate COVID-19 in outpatients ≥12 years old who weigh at least 40 kg and are at high risk of progressing to severe disease, including hospitalization or death. Paxlovid was the first oral antiviral drug to be authorized in the US for treatment of COVID-19; Merck's oral antiviral drug molnupiravir was granted an EUA for treatment of COVID-19 on December 23, 2021. The IV antiviral drug remdesivir (Veklury) was approved by the FDA in 2020 for treatment of COVID-19 in hospitalized patients.
Issue 1642 · January 24, 2022 Free
Molnupiravir - An Oral Antiviral Drug for COVID-19

The investigational oral antiviral drug molnupiravir (Merck/Ridgeback Biotherapeutics) was granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of mild to moderate COVID-19 in…

Med Lett Drugs Ther. 2022 Jan 24; 64(1642):10-1
The investigational oral antiviral drug molnupiravir (Merck/Ridgeback Biotherapeutics) was granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of mild to moderate COVID-19 in outpatients ≥18 years old who are at high risk of progressing to severe disease, including hospitalization or death (see Table 1), and for whom alternative treatment options are not available or clinically appropriate. Paxlovid (Pfizer), nirmatrelvir copackaged with ritonavir, was granted an EUA on December 22, 2021. The IV antiviral drug remdesivir (Veklury) was approved by the FDA in 2020 for treatment of COVID-19 in hospitalized patients.
Issue 1642 · January 24, 2022 Free
COVID-19 Updates

On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody combinations…

Med Lett Drugs Ther. 2022 Jan 24; 64(1642):16
On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody combinations casirivimab plus imdevimab (REGEN-COV) and bamlanivimab plus etesevimab are not active against the Omicron variant of SARS-CoV-2.
Issue 1641 · January 10, 2022 Free
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19

The FDA has issued an Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab ( Evusheld – AstraZeneca) to be administered concomitantly by IM…

Med Lett Drugs Ther. 2022 Jan 10; 64(1641):1-2
The FDA has issued an Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab ( Evusheld – AstraZeneca) to be administered concomitantly by IM injection for pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of severe allergy that prevents their vaccination against COVID-19 or moderate or severe immune compromise (see Table 1). They are the first drugs to be authorized by the FDA for this indication. Two other pairs of antibodies, bamlanivimab plus etesevimab (Lilly) and casirivimab plus imdevimab (REGEN-COV), are authorized for post-exposure prophylaxis of COVID-19.
Issue 1640 · December 27, 2021 Free
In Brief: Booster Doses of mRNA-Based COVID-19 Vaccines for All Adults

On November 19, the FDA expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a…

Med Lett Drugs Ther. 2021 Dec 27; 63(1640):201-2
On November 19, the FDA expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a booster dose for all adults ≥18 years old after primary immunization with either the same COVID-19 vaccine or a different one. Booster doses of these vaccines were previously authorized only for select populations (age ≥65 years or persons at high risk for severe COVID-19). The EUA for the adenovirus-based vaccine manufactured by Johnson & Johnson was amended in October 2021 to include administration of a booster dose for all adults ≥18 years old after primary immunization with the Johnson & Johnson vaccine.
Issue 1638 · November 29, 2021 Free
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old

The FDA has issued an Emergency Use Authorization (EUA) for a lower-strength (10 mcg/0.2 mL) formulation of the mRNA-based COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) for use in children 5-11…

Med Lett Drugs Ther. 2021 Nov 29; 63(1638):185
The FDA has issued an Emergency Use Authorization (EUA) for a lower-strength (10 mcg/0.2 mL) formulation of the mRNA-based COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) for use in children 5-11 years old. The original formulation of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for use in persons ≥16 years old and available under an EUA for use in adolescents 12-15 years old.
Issue 1638 · November 29, 2021 Free
Booster Doses of COVID-19 Vaccines

The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine…

Med Lett Drugs Ther. 2021 Nov 29; 63(1638):186-8
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine manufactured by Johnson & Johnson/Janssen to include administration of a booster dose in select populations after primary immunization with either the same COVID-19 vaccine or a different one.
Issue 1637 · November 15, 2021
Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were…

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):177-84
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Issue 1635 · October 18, 2021 Free
Booster Dose of the Pfizer/BioNTech COVID-19 Vaccine (Comirnaty)

On September 22, on the advice of its Vaccines and Related Biologic Products Advisory Committee, the FDA expanded the Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine…

Med Lett Drugs Ther. 2021 Oct 18; 63(1635):161-2
On September 22, on the advice of its Vaccines and Related Biologic Products Advisory Committee, the FDA expanded the Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine (Comirnaty) to include administration of a booster dose ≥6 months after a 2-dose primary series in adults who are ≥65 years old or at high risk for severe COVID-19 because of an underlying medical condition or frequent institutional or occupational exposure to SARS-CoV-2 (see Table 1). The FDA Advisory Committee recommended against authorization of a booster dose of Comirnaty for all persons ≥16 years old, citing a lack of adequate data.
Issue 1635 · October 18, 2021 Free
Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19

In February 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibodies bamlanivimab and etesevimab (Lilly) for use together to treat mild to moderate COVID-19 in…

Med Lett Drugs Ther. 2021 Oct 18; 63(1635):163-4
In February 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibodies bamlanivimab and etesevimab (Lilly) for use together to treat mild to moderate COVID-19 in persons ≥12 years old who weigh ≥40 kg and are at high risk of progression to severe disease or hospitalization. The FDA has now expanded this EUA to allow use of the antibodies together for post-exposure prophylaxis of COVID-19 in such persons if they are not fully vaccinated against COVID-19 or are unlikely to have an adequate immune response to full vaccination and have been in close contact with a SARS-CoV-2-infected individual or are likely to be exposed to SARS-CoV-2 in the setting of an institutional outbreak (see Table 1). Bamlanivimab plus etesevimab is the second monoclonal antibody combination to receive an EUA for post-exposure prophylaxis of COVID-19; casirivimab plus imdevimab (REGEN-COV) was authorized earlier.
Issue 1633 · September 20, 2021 Free
In Brief: Third Dose of mRNA-based COVID-19 Vaccines for Immunocompromised Persons

The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a third dose in…

Med Lett Drugs Ther. 2021 Sep 20; 63(1633):145-6
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a third dose in persons ≥12 years old (Pfizer/BioNTech) or ≥18 years old (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent (see Table 1).
Issue 1631 · August 23, 2021 Free
Casirivimab and Imdevimab (REGEN-COV) for Post-Exposure Prophylaxis of COVID-19

The investigational monoclonal antibodies casirivimab and imdevimab ( REGEN-COV – Regeneron) have been available in the US under an Emergency Use Authorization (EUA) since late 2020 for use together to treat…

Med Lett Drugs Ther. 2021 Aug 23; 63(1631):130-1
The investigational monoclonal antibodies casirivimab and imdevimab ( REGEN-COV – Regeneron) have been available in the US under an Emergency Use Authorization (EUA) since late 2020 for use together to treat mild to moderate COVID-19 in persons ≥12 years old who weigh ≥40 kg and are at high risk of progression to severe disease or hospitalization. The FDA has now expanded this EUA to allow use of the antibodies together for post-exposure prophylaxis of COVID-19 in such persons, if they are not fully vaccinated against COVID-19 or are unlikely to have an adequate immune response to full vaccination and have been in close contact with a SARS-CoV-2-infected individual or are likely to be exposed to SARS-CoV-2 in the setting of an institutional outbreak (see Table 1). Casirivimab and imdevimab are the first drugs to receive an EUA for post-exposure prophylaxis of COVID-19.
Issue 1630 · August 9, 2021
Ponesimod (Ponvory) for Multiple Sclerosis

The FDA has approved ponesimod ( Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated…

Med Lett Drugs Ther. 2021 Aug 9; 63(1630):123-5
The FDA has approved ponesimod ( Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Ponesimod is the fourth oral S1P receptor modulator to be approved in the US for once-daily treatment of relapsing forms of MS; ozanimod (Zeposia) and siponimod (Mayzent) are also approved for use in adults, and fingolimod (Gilenya) is indicated for use in patients ≥10 years old.
Issue 1630 · August 9, 2021 Free
In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine

On July 12, 2021, the FDA added a warning to the Fact Sheet for the Johnson & Johnson (Janssen) adenovirus-based COVID-19 vaccine about an increased risk of Guillain-Barré syndrome (GBS) following…

Med Lett Drugs Ther. 2021 Aug 9; 63(1630):121
On July 12, 2021, the FDA added a warning to the Fact Sheet for the Johnson & Johnson (Janssen) adenovirus-based COVID-19 vaccine about an increased risk of Guillain-Barré syndrome (GBS) following administration of the product.
Issue 1629 · July 26, 2021 Free
An EUA for Tocilizumab (Actemra) for COVID-19

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):113-4
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA for various indications, including rheumatoid arthritis and juvenile idiopathic arthritis.
Issue 1627 · June 28, 2021 Free
An EUA for Sotrovimab for Treatment of COVID-19

The investigational monoclonal antibody sotrovimab (VIR-7831; GSK/Vir Biotechnology) has been granted an FDA Emergency Use Authorization (EUA) for treatment of mild to moderate COVID-19 in patients ≥12 years…

Med Lett Drugs Ther. 2021 Jun 28; 63(1627):97-8
The investigational monoclonal antibody sotrovimab (VIR-7831; GSK/Vir Biotechnology) has been granted an FDA Emergency Use Authorization (EUA) for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease, including hospitalization and death.1 Two other monoclonal antibody regimens are authorized for the same indication: casirivimab (REGN10933) and imdevimab (REGN10987) administered together, and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016) administered together. The FDA revoked its EUA for bamlanivimab alone in April 2021 because an increasing percentage of COVID-19 cases in the US are being caused by SARS-CoV-2 variants that are resistant to monotherapy with the drug.
Issue 1625 · May 31, 2021 Free
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old

On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in…

Med Lett Drugs Ther. 2021 May 31; 63(1625):81
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in persons ≥16 years old since December 2020.
Issue 1624 · May 17, 2021 Free
In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)

On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson & Johnson adenovirus-based COVID-19 vaccine resume despite its…

Med Lett Drugs Ther. 2021 May 17; 63(1624):e1
On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson & Johnson adenovirus-based COVID-19 vaccine resume despite its association with development of thrombosis with thrombocytopenia syndrome (TTS). Administration of the vaccine had been paused on April 13 because of 6 reports of TTS, but after completing a data review that identified a further 9 cases associated with the formulation, the agencies concluded that the benefits of the vaccine outweighed its risks. About 7.98 million doses of the single-dose vaccine had been administered in the US at the time of the review.
Issue 1623 · May 3, 2021 Free
Fluvoxamine for COVID-19?

A recent article in JAMA and an interview of its senior author on 60 Minutes have heightened interest in off-label use of the oral selective serotonin reuptake inhibitor (SSRI) fluvoxamine ( Luvox , and…

Med Lett Drugs Ther. 2021 May 3; 63(1623):69-70
A recent article in JAMA and an interview of its senior author on 60 Minutes have heightened interest in off-label use of the oral selective serotonin reuptake inhibitor (SSRI) fluvoxamine ( Luvox , and generics) to treat COVID-19.
Issue 1623 · May 3, 2021 Free
In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)

On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and…

Med Lett Drugs Ther. 2021 May 3; 63(1623):e1
On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and thrombocytopenia that occurred following administration of the vaccine. In an April 14 emergency meeting, the Advisory Committee on Immunization Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million people in the US have received the Johnson & Johnson vaccine.
Issue 1621 · April 5, 2021 Free
An EUA for Bamlanivimab and Etesevimab for COVID-19

The FDA has issued an Emergency Use Authorization (EUA) for Lilly's investigational monoclonal antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) to be administered together for treatment of mild…

Med Lett Drugs Ther. 2021 Apr 5; 63(1621):49-50
The FDA has issued an Emergency Use Authorization (EUA) for Lilly's investigational monoclonal antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) to be administered together for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease and/or hospitalization (see Table 1). Bamlanivimab received an EUA for use as monotherapy in such patients in November 2020. Regeneron's investigational monoclonal antibodies casirivimab (REGN10933) and imdevimab (REGN10987) are also authorized for use together for the same indication.
Issue 1620 · March 22, 2021 Free
FDA Authorizes Johnson & Johnson COVID-19 Vaccine

On February 27, 2021, the FDA issued an Emergency Use Authorization (EUA) for the Johnson & Johnson adenovirus-based vaccine for prevention of COVID-19 in persons ≥18 years old. It is the third COVID-19…

Med Lett Drugs Ther. 2021 Mar 22; 63(1620):41-2
On February 27, 2021, the FDA issued an Emergency Use Authorization (EUA) for the Johnson & Johnson adenovirus-based vaccine for prevention of COVID-19 in persons ≥18 years old. It is the third COVID-19 vaccine to become available in the US and the first to require only a single dose. Two-dose mRNA-based vaccines manufactured by Pfizer-BioNTech and Moderna received EUAs in December 2020.
Issue 1616 · January 25, 2021 Free
FDA Authorizes Moderna COVID-19 Vaccine

On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine…

Med Lett Drugs Ther. 2021 Jan 25; 63(1616):9-10
On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine received an FDA EUA for the same indication in persons ≥16 years old on December 11, 2020.
Issue 1616 · January 25, 2021 Free
Antibacterial Drugs for Community-Acquired Pneumonia

Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in…

Med Lett Drugs Ther. 2021 Jan 25; 63(1616):10-5
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Issue 1615 · January 11, 2021 Free
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine

The FDA has issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA-based vaccine for prevention of COVID-19 in persons ≥16 years old.

Med Lett Drugs Ther. 2021 Jan 11; 63(1615):1-2
The FDA has issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA-based vaccine for prevention of COVID-19 in persons ≥16 years old.
Issue 1614 · December 28, 2020 Free
An EUA for Casirivimab and Imdevimab for COVID-19

The FDA has issued an Emergency Use Authorization (EUA) for Regeneron's investigational monoclonal antibodies casirivimab and imdevimab (REGEN-COV) to be administered together by IV infusion or SC injection…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):201-2
The FDA has issued an Emergency Use Authorization (EUA) for Regeneron's investigational monoclonal antibodies casirivimab and imdevimab (REGEN-COV) to be administered together by IV infusion or SC injection for treatment of mild to moderate COVID-19 in adults and pediatric patients (≥12 years old and weigh ≥40 kg) who are at high risk of progressing to severe COVID-19 and/or hospitalization.
Issue 1614 · December 28, 2020 Free
An EUA for Baricitinib (Olumiant) for COVID-19

The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):202-3
The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the EUA requires that baricitinib be used in combination with the IV antiviral drug remdesivir (Veklury) . Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the FDA for treatment of COVID-19 in hospitalized patients ≥12 years old who weigh ≥40 kg; it is available under an EUA for treatment of other hospitalized patients.
Issue 1614 · December 28, 2020
Ofatumumab (Kesimpta) for Multiple Sclerosis

The FDA has approved a subcutaneous formulation of the recombinant human anti-CD20 antibody ofatumumab ( Kesimpta – Novartis) for treatment of adults with relapsing forms of multiple sclerosis (MS),…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):203-5
The FDA has approved a subcutaneous formulation of the recombinant human anti-CD20 antibody ofatumumab ( Kesimpta – Novartis) for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Kesimpta is the second anti-CD20 antibody to be approved for these indications; IV ocrelizumab (Ocrevus) , which is also approved for treatment of primary progressive MS, was the first. An IV formulation of ofatumumab (Arzerra) has been available for treatment of chronic lymphocytic leukemia (CLL) since 2010.
Issue 1612 · November 30, 2020 Free
An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19

The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19…

Med Lett Drugs Ther. 2020 Nov 30; 62(1612):185-6
The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table 1).
Issue 1612 · November 30, 2020 Free
Remdesivir (Veklury) for COVID-19

The FDA has approved the antiviral drug remdesivir ( Veklury – Gilead) for IV treatment of COVID-19 in hospitalized patients who are ≥12 years old and weigh ≥40 kg. Hospitalized children who are <12…

Med Lett Drugs Ther. 2020 Nov 30; 62(1612):186-8
The FDA has approved the antiviral drug remdesivir ( Veklury – Gilead) for IV treatment of COVID-19 in hospitalized patients who are ≥12 years old and weigh ≥40 kg. Hospitalized children who are <12 years old or weigh <40 kg can receive remdesivir through an Emergency Use Authorization (EUA). Remdesivir is the first drug to be approved in the US for treatment of COVID-19.
Issue 1612 · November 30, 2020
Drugs for Acne

Acne is common among adolescents and young adults, but its prevalence appears to have increased in people of all ages due to prolonged wearing of masks during the COVID-19 pandemic. Guidelines for treatment of…

Med Lett Drugs Ther. 2020 Nov 30; 62(1612):188-91
Acne is common among adolescents and young adults, but its prevalence appears to have increased in people of all ages due to prolonged wearing of masks during the COVID-19 pandemic. Guidelines for treatment of acne were last published in 2016.
Issue 1610 · November 2, 2020
Antiviral Drugs for Influenza for 2020-2021

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1).…

Med Lett Drugs Ther. 2020 Nov 2; 62(1610):169-73
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1609 · October 19, 2020 Free
Timing of Remdesivir for COVID-19

Remdesivir ( Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized…

Med Lett Drugs Ther. 2020 Oct 19; 62(1609):161
Remdesivir ( Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized patients. An earlier EUA limited use of the drug to patients hospitalized with severe disease.
Issue 1595 · April 6, 2020 Free
Some Drugs for COVID-19

The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in…

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):49-50
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Issue 1595 · April 6, 2020 Free
Table: Treatments Considered for COVID-19 (Archived) (online only)

View the Table: Treatments Considered for COVID-19

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):e1-289
View the Table: Treatments Considered for COVID-19